tiprankstipranks

Replimune Group price target raised to $17 from $13 at Barclays

Barclays raised the firm’s price target on Replimune Group to $17 from $13 and keeps an Overweight rating on the shares. The company reported positive topline data for RP1 plus nivolumab in advanced melanoma by central review which was consistent with prior data presented by investigator assessment, the analyst tells investors in a research note. The firm says the data continues to support potential accelerated approval.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue